The global blood culture tests market size was valued at USD 6.67 billion in 2025 and is projected to grow from USD 7.36 billion in 2026 to USD 16.14 billion by 2034, registering a CAGR of 10.32% during the forecast period from 2026 to 2034. North America dominated the blood culture tests market with a market share of 38.6% in 2025.
Blood culture tests are laboratory tests used to detect microorganisms, such as bacteria or fungi, that may be present in a person’s bloodstream. A healthcare professional collects blood samples and places them into specialized culture bottles that provide suitable conditions for microorganisms to grow. The samples are then monitored in a laboratory, and if growth occurs, further testing can help identify the organism and determine which antimicrobial medicines may be effective. Blood cultures are commonly used when a serious bloodstream infection is suspected, including conditions such as sepsis. Because contamination from microorganisms on the skin can affect results, careful collection and handling of the blood sample are important for obtaining reliable findings.
Download a Free Sample To learn more about this report,
Rapid Blood Culture Technologies Accelerate Sepsis Diagnosis
The blood culture tests market is increasingly focused on shortening the time needed to identify bloodstream infections and guide appropriate treatment. Traditional blood culture workflows can require considerable time for organism identification and susceptibility testing, which can delay targeted therapy. Newer automated systems, faster identification methods, and molecular technologies are being developed to help laboratories detect clinically important pathogens more efficiently. Faster diagnosis is particularly important in sepsis care, where timely treatment can significantly influence patient outcomes.
In February 2025, bioMérieux introduced the BIOFIRE FILMARRAY Blood Culture Identification 2 Panel in additional markets, expanding access to a molecular diagnostic approach that can identify a broad range of bacterial and yeast pathogens directly from positive blood culture samples. The technology is designed to provide actionable information earlier in the diagnostic process and support faster treatment decisions.
Automation and Multiplex Testing Improve Laboratory Efficiency
The blood culture tests market is also moving toward greater automation and multiplex testing as clinical laboratories seek to process samples more consistently while reducing manual workload. Automated blood culture instruments can continuously monitor samples for microbial growth and alert laboratory staff when a culture becomes positive. When combined with multiplex identification panels, these systems can streamline the transition from detection to organism identification and help laboratories manage growing diagnostic workloads more efficiently.
In June 2025, Becton Dickinson expanded its BD Kiestra laboratory automation portfolio with enhanced microbiology workflow capabilities, supporting automated handling and processing of microbiology samples. The development reflects the broader movement toward connected laboratory systems that improve workflow consistency and help microbiologists respond to positive cultures more efficiently.
Rising Burden of Bloodstream Infections and Sepsis
The blood culture tests market is being driven by the continued burden of bloodstream infections and sepsis, which require timely identification of infectious organisms to guide appropriate treatment. Blood culture testing remains an important laboratory method for detecting microorganisms in blood and supporting subsequent antimicrobial susceptibility testing. Growing awareness of antimicrobial resistance is also increasing the need for reliable microbiological diagnosis and targeted antibiotic treatment. These developments are strengthening blood culture tests market demand and influencing blood culture tests market trends toward faster identification, automated monitoring, and improved laboratory workflows.
In October 2025, the World Health Organization published its Global Antibiotic Resistance Surveillance Report, drawing on more than 23 million bacteriologically confirmed cases, including bloodstream infections. The report emphasized the growing importance of surveillance and reliable diagnostic information for understanding resistance patterns and supporting appropriate treatment decisions.
Long Turnaround Times and Infrastructure Requirements
The market faces restraints because conventional blood culture testing can require extended incubation and additional identification and susceptibility testing before clinicians receive complete results. The process also depends on laboratory infrastructure, trained personnel, appropriate sample collection, and contamination-control procedures. These requirements can make testing more difficult in healthcare facilities with limited laboratory resources. Such limitations create blood culture tests industry challenges and can influence blood culture tests market development, particularly in low-resource and decentralized healthcare settings.
In August 2025, the World Health Organization highlighted limitations associated with existing diagnostic approaches for serious bacterial infections, including blood cultures. The organization identified long turnaround times, relatively high costs, infrastructure requirements, and limited accessibility as important barriers to timely diagnosis, particularly for newborns and young infants.
Development of Rapid Identification and Antimicrobial Susceptibility Testing
The market presents significant opportunities through automated blood culture systems, rapid organism identification, and faster antimicrobial susceptibility testing technologies. Reducing the time between a positive culture and actionable susceptibility information can help clinicians make more targeted treatment decisions and support antimicrobial stewardship. Growing demand for rapid microbiological diagnostics is creating new blood culture tests market opportunities and supporting blood culture tests market growth as laboratories seek to improve turnaround times without compromising diagnostic accuracy.
In July 2026, the U.S. Food and Drug Administration cleared bioMérieux's VITEK REVEAL GN AST Assay and VITEK REVEAL AST System for antimicrobial susceptibility testing using positive blood culture samples. The regulatory decision reflected continued development of technologies designed to provide susceptibility information directly from positive blood culture samples.
Improving Diagnostic Speed While Maintaining Accuracy and Reliability
The blood culture tests market continues to face challenges in achieving faster diagnostic results while maintaining sensitivity, specificity, contamination control, and reliable organism identification. Laboratories must also manage different bacterial and fungal pathogens, antimicrobial resistance patterns, sample volumes, and clinical conditions that can affect test performance. These requirements are shaping the blood culture tests market outlook and encouraging development of automated monitoring systems, molecular technologies, rapid susceptibility testing, and integrated laboratory workflows.
In May 2026, the U.S. Food and Drug Administration cleared the BD BACTEC FXI Culture System, an automated blood culturing system intended for microbiology laboratories. The regulatory decision demonstrated continued development of automated platforms designed to improve blood culture processing and laboratory efficiency while maintaining standardized testing workflows.
Automated Blood Culture Methods Segment Dominated the Blood Culture Tests Market with 63.2% Share in 2025
The automated blood culture methods segment dominated the global blood culture tests market with a 63.2% share in 2025, driven by the increasing demand for rapid, standardized, and efficient detection of bloodstream infections. Automated systems can continuously monitor culture samples and provide timely alerts when microbial growth is detected, helping laboratories streamline testing workflows and support faster clinical decision-making. Growing hospital adoption of laboratory automation and the need for improved diagnostic efficiency are supporting the segment.
Conventional blood culture methods continue to be used across laboratories because of their established workflows and suitability for facilities with more limited automation infrastructure. These methods remain relevant for routine microbiological testing and continue to contribute to bloodstream infection diagnosis.
Request Customizationto receive a tailored report.
Software and Services Segment is Projected to Register the Fastest Growth in the Blood Culture Tests Market at a CAGR of 10.76%
The software and services segment is projected to register the fastest growth in the global blood culture tests market at a CAGR of 10.76% during 2026–2034, driven by increasing adoption of connected diagnostic systems, laboratory information management, data integration, system maintenance, and technical support. Software solutions can improve workflow management, data handling, result tracking, and integration between blood culture instruments and laboratory systems. Growing digitalization of diagnostic laboratories is further supporting demand for related services.
Consumables remain an important product category because blood culture testing requires continuous use of culture bottles, media, reagents, and other laboratory supplies. Instruments support automated and conventional testing workflows, while ongoing technological improvements are encouraging laboratories to upgrade diagnostic equipment and expand testing capabilities.
Bacterial Segment Dominated the Blood Culture Tests Market with 72.6% Share in 2025
The bacterial segment dominated the global blood culture tests market with a 72.6% share in 2025, driven by the high clinical importance of detecting bacterial bloodstream infections and sepsis. Blood culture testing plays a central role in identifying bacterial pathogens and guiding appropriate antimicrobial treatment. Increasing awareness of sepsis, growing hospital testing volumes, and the need for timely pathogen identification are supporting demand for bacterial blood culture testing.
The fungal segment continues to gain importance as healthcare providers improve detection of invasive fungal infections, particularly among vulnerable patient populations. Other applications contribute to the market through testing requirements involving less common microorganisms and specialized diagnostic needs.
Speak to an Analystto discuss market opportunities.
North America accounted for the largest share of the global blood culture tests market, representing 38.6% of total revenue and reaching USD 2.57 billion in 2025. The region is projected to grow at a CAGR of 8.72% during 2026–2034. Strong healthcare infrastructure, increasing prevalence of bloodstream infections, growing demand for rapid diagnostic testing, and widespread adoption of automated laboratory systems are supporting regional market growth. Increasing emphasis on early diagnosis and appropriate antimicrobial treatment is also contributing to demand for blood culture testing.
The US market was valued at approximately USD 2.17 billion in 2025, making it the largest contributor in North America. High healthcare spending, advanced clinical laboratory infrastructure, increasing hospital testing volumes, and growing awareness of sepsis diagnosis are supporting market development. Continued adoption of automated blood culture systems and rapid diagnostic technologies is also strengthening demand.
Canada's market reached approximately USD 0.40 billion in 2025. Growing demand for infectious disease diagnostics, expanding hospital laboratory capabilities, and increasing focus on early detection of bloodstream infections are supporting market growth. Adoption of automated laboratory technologies is also contributing to market development.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe accounted for 29.4% of the global blood culture tests market, reaching USD 1.96 billion in 2025, and is projected to register the fastest CAGR of 10.48% during 2026–2034. Increasing awareness of sepsis and bloodstream infections, strong diagnostic infrastructure, and growing demand for accurate and timely microbiological testing are driving regional growth. Continued investment in laboratory automation and advanced diagnostic technologies is further supporting market expansion.
The UK market was valued at approximately USD 0.35 billion in 2025. Increasing focus on sepsis recognition, hospital infection management, and timely microbiological diagnosis is supporting demand for blood culture testing. Continued improvements in laboratory automation and diagnostic workflows are also contributing to market development.
Germany's market accounted for approximately USD 0.45 billion in 2025. A well-established healthcare system, strong clinical laboratory infrastructure, and increasing focus on infectious disease diagnosis are supporting market growth. Growing adoption of automated blood culture systems and advanced microbiology technologies is further contributing to demand.
Asia Pacific accounted for 22.7% of the global blood culture tests market, valued at USD 1.51 billion in 2025, and is projected to grow at a CAGR of 9.96% during 2026–2034. Expanding healthcare infrastructure, increasing hospitalisation, rising awareness of infectious diseases, and improving access to diagnostic testing are driving regional growth. Growing investment in laboratory automation and advanced microbiological diagnostics is also supporting adoption.
Japan's market generated approximately USD 0.25 billion in 2025. An advanced healthcare system, aging population, strong hospital infrastructure, and growing demand for accurate infectious disease diagnosis are supporting market development. Increasing use of automated laboratory systems is also contributing to market growth.
China accounted for a major share of the Asia Pacific market, reaching approximately USD 0.70 billion in 2025. Expanding hospital infrastructure, increasing diagnostic testing, growing awareness of bloodstream infections, and rising healthcare expenditure are supporting market growth. Greater adoption of automated microbiology systems is further improving access to blood culture testing.
Latin America accounted for 5.4% of the global blood culture tests market, reaching USD 0.36 billion in 2025, and is projected to grow at a CAGR of 8.41% during 2026–2034. Expanding healthcare infrastructure, increasing demand for infectious disease diagnostics, and improving access to laboratory testing are supporting regional development. Greater awareness of sepsis and the importance of early diagnosis is also creating opportunities for blood culture testing.
Brazil's market was valued at approximately USD 0.18 billion in 2025. Expanding hospital networks, increasing demand for clinical diagnostics, and growing attention to bloodstream infections are supporting market development. Improvements in laboratory infrastructure and diagnostic capabilities are also contributing to adoption.
Mexico's market reached approximately USD 0.08 billion in 2025. Increasing healthcare investment, expanding diagnostic laboratories, and growing demand for infectious disease testing are supporting market growth. Greater awareness of timely diagnosis and improvements in laboratory capabilities are also contributing to market development.
Middle East and Africa accounted for 3.9% of the global blood culture tests market, totalling USD 0.26 billion in 2025, and is projected to grow at a CAGR of 7.88% during 2026–2034. Improving healthcare infrastructure, increasing investment in diagnostic services, rising awareness of infectious diseases, and expanding hospital capacity are supporting regional growth. Greater access to laboratory testing and modern diagnostic technologies is also creating additional opportunities.
The UAE market was valued at approximately USD 0.06 billion in 2025. Advanced healthcare infrastructure, increasing investment in diagnostic services, and growing demand for rapid infectious disease testing are supporting market development. Adoption of automated laboratory technologies is also contributing to market growth.
Africa's market reached approximately USD 0.20 billion in 2025. Expanding healthcare infrastructure, increasing access to diagnostic laboratories, and growing demand for infectious disease testing are supporting market development. Continued investment in laboratory capacity and improved awareness of bloodstream infections are expected to create further opportunities for blood culture testing.
The global blood culture tests market is highly competitive, with diagnostic companies developing automated blood culture systems, microbial identification technologies, molecular testing platforms, and antimicrobial susceptibility solutions. The top players in the industry include Autobio Diagnostics Co. Ltd., Becton Dickinson and Company, bioMérieux SA, Bruker Corporation, F. Hoffmann-La Roche Ltd., Luminex Corporation, Neogen Corporation (Abtek Biologicals), OpGen Inc., T2 Biosystems Inc., Thermo Fisher Scientific Inc., and others.
Industry participants are focusing on making bloodstream infection testing faster, more accurate, and easier to integrate into clinical laboratory workflows. Companies are also developing technologies that can identify pathogens and antimicrobial resistance markers more quickly after a positive blood culture, helping clinicians make treatment decisions sooner. bioMérieux, for example, offers the BACT/ALERT® automated blood culture system for detecting microorganisms in blood and other normally sterile body fluids.
bioMérieux SA: An Emerging Market Player
bioMérieux is a prominent participant in the blood culture tests market, with a long-established portfolio of microbiology and infectious disease diagnostic technologies. Its solutions support laboratories in detecting bloodstream infections and identifying microorganisms responsible for serious infections.
bioMérieux continues to advance its blood culture portfolio through automated detection systems and complementary identification technologies. Its BACT/ALERT® systems are designed for continuous monitoring of blood culture bottles, helping laboratories detect microbial growth and move positive samples into subsequent identification and susceptibility testing workflows. The company's broader microbiology portfolio also supports faster pathogen identification and antimicrobial-resistance assessment.
Customize This Report to Match Your Strategic Objectives
Author's Details
Healthcare Lead
Debashree Bora is a strategic healthcare research professional with nearly eight years of hands on experience in market intelligence, encompassing primary research, secondary research, market estimation, and consulting engagements. She specializes in pharmaceutical, biotechnology, medical devices, healthcare services, clinical trials, and healthcare outsourcing sectors, providing actionable insights on evolving industry trends, regulatory landscapes, competitive dynamics, and market opportunities. Debashree’s research helps global clients evaluate market potential, identify growth opportunities, strengthen commercial strategies, and make informed business decisions.
Her work focuses on assessing treatment landscapes, outsourcing models, technology adoption, market access dynamics, regulatory developments, and competitive positioning across healthcare and life sciences industries. Debashree has consistently supported organizations in understanding market gaps, evaluating revenue potential, developing market entry strategies, and shaping expansion plans across complex and fast evolving healthcare markets.
With a strong analytical foundation and structured research approach, she excels at synthesizing large datasets, stakeholder inputs, and market signals into actionable insights that guide strategic decision making. Her healthcare expertise enables her to connect clinical, commercial, and operational developments with business opportunities, helping stakeholders anticipate shifts and capitalize on emerging growth areas. Debashree’s consulting oriented mindset and deep healthcare industry understanding make her a trusted advisor to businesses navigating dynamic and rapidly evolving healthcare markets.
Biologics Market Size, Share, Growth, Analysis, Report, 2034
Cell Surface Markers Detection Market Size, Share, Growth, 2034
Paper Diagnostics Market Size, Share, Growth, Forecast, 2034
Organ on Chip Market Size, Share, Growth, Analysis, 2034
Animal Model Market Size, Share, Growth, Analysis, Report, 2034
Capillary Electrophoresis Market Size, Share, Growth, Analysis, 2034
We are featured on:
sales@straitsresearch.com